Holmbom

Patrick Holmbom, As SE

Patent application number	Description	Published
20130240816	Edge Protection System Using Cantilevered Counterweight - An edge protection system including spaced counterweights each having a connecting bracket on one side thereof. Cantilever arms each have vertical legs on opposite ends, with one leg pivotally secured to the counterweights and the other leg secured to hubs. The vertical legs may selectively support the cantilever arm at a height sufficient to allow workers to walk upright beneath the arm. Wedges connect ledger ends to connecting wheels on hub vertical posts, and secure a stiffener to the wheel and ledger sections. Counterweights have a U-shaped bracket and a plurality of weight blocks. The blocks are selectively stacked on the bracket with one upright leg extending through weight block center openings and the other upright leg in side slots of the blocks. A trolley has a carrying connector for connecting to a connector of the one upright leg on top of the counterweight for transporting the counterweight.	09-19-2013

Patent application number	Description	Published
20130281381	PHARMACEUTICAL COMPOSITIONS COMPRISING 8-SUBSTITUTED DIBENZYLBUTYROLACTONE LIGNANS - Therapeutic compositions comprising at least one 8-substituted-dibenzylbutyrolactone lignan, preferably a lignan is selected from the group of nortrachelogenin, diasteromeric forms of nortrachelogenin, isomeric forms of nortrachelogenin and combinations thereof as well as 8-methylmatairesinol and 8-methyldimethylmatairesinol, for use in a method of treating cancer or a similar condition wherein the growth factor signaling pathway of a mammal is deregulated. The invention also provides therapeutic pharmaceutical combinations comprising a hydroxy-dibenzylbutyrolactone lignan and at least one TRAIL receptor agonist. The hydroxy-dibenzylbutyrolactone lignans and a TRAIL receptor agonist can be used as a combined preparation for administration to a patient simultaneously, separately or spaced out over a period of time in treating cancer.	10-24-2013

Patent application number	Description	Published
20160120937	Pharmaceutical compositions comprising 8-substituted dibenzylbutyrolactone lignans - Therapeutic compositions comprising at least one 8-substituted-dibenzylbutyrolactone lignan, preferably a lignan is selected from the group of nortrachelogenin, diasteromeric forms of nortrachelogenin, isomeric forms of nortrachelogenin and combinations thereof as well as 8-methylmatairesinol and 8-methyldimethylmatairesinol, for use in a method of treating cancer or a similar condition wherein the growth factor signaling pathway of a mammal is deregulated. The invention also provides therapeutic pharmaceutical combinations comprising a hydroxy-dibenzylbutyrolactone lignan and at least one TRAIL receptor agonist. The hydroxy-dibenzylbutyrolactone lignans and a TRAIL receptor agonist can be used as a combined preparation for administration to a patient simultaneously, separately or spaced out over a period of time in treating cancer.	05-05-2016